Tic‐Talk: Voices on Tourette's Labelling

Citations Over TimeTop 14% of 2025 papers

Abstract

Tourette syndrome (TS) is a neurodevelopmental disorder characterized by involuntary motor and vocal tics. Georges Gilles de la Tourette, the first neurologist to describe the condition in 1885, identified 9 cases with motor and vocal tics. However, he concluded that only 4 patients had a true diagnosis of TS, with the others showing anxiety, obsessive-compulsive disorder (OCD), and other behaviors.1, 2 Although TS is often diagnosed during childhood, its symptoms peak between the age 8 and 12 years, a period of physical and social development in which patients are potentially affected by stigma, shaping their view of the condition in their later life. One of the main factors contributing to the social stigma related to TS is the misrepresentation of the typical presentation of tics, focusing on a minor cohort of people with TS who have coprolalia. This portrayal has been reinforced by traditional media and, more recently, amplified through social media platforms like TikTok and YouTube.3-5 These platforms, particularly popular among younger audiences, promote sensational, outrageous, or humorous content to attract views and shares.6-8 Although such videos often include hashtags like #tourettesyndrome, they predominantly highlight extreme or severe cases. As a result, viewers are led to believe that these rare and exaggerated presentations are typical of TS, perpetuating misconceptions and reinforcing negative stereotypes about the condition. This has significant implications for individuals living with the condition and their caregivers, particularly affecting areas such as education, social life, and employment.9 In our clinical work at Evelina London, many patients voiced concerns about the TS label, citing stigma and its impact on perception. Several families highlighted their preference for different names such as tics, tic spectrum, or tic disorder. This, alongside a literature review to explore concepts around labeling and stigma in the movement clinics, revealed dissatisfaction around the current language used in TS, and mostly in the wider context of neurodiversity. In NeuroTribes, for example, Silberman criticizes the traditional medical model for its deficit-centric view, predominantly led by non-autistic researchers, in contrast to the neurodiversity paradigm. The latter supports the neuro-affirmative movement, which perceives neurodivergence as a natural genetic variation rather than a deficit, focusing on the experiences and preferences of neurodiverse individuals.10, 11 In recent years, there has been a growing movement among autism advocates to reframe autism spectrum disorder (ASD) within the framework of neurodiversity, promoting strength-based language and approaches in assessments and interventions, disagreeing on the use of “syndrome” and “disorder.”12 This paradigm shift is particularly relevant among the TS community, as patients are often diagnosed with coexisting attention-deficit hyperactivity disorder (ADHD), OCD or behaviors (OCD/B), and ASD.13 Although many studies regarding “diagnostic labelling” primarily address ASD or ADHD,14-16 a subset of studies explore a reconceptualization of TS. This moves away from a traditional emphasis on tic reduction toward a “letting be” approach, which prioritizes acceptance and accommodation of tics as part of an individual's neurodiverse experience.17, 18 Overall, these studies often focus on health care professionals' perspectives, lacking an exploration of whether patients, caregivers, and health care professionals share similar perspectives on labelling TS. This study aims to investigate the views of patients, caregivers, and health care professionals regarding current Tourette's syndrome (TS) labeling and other patient-centric alternatives. We designed a pilot study with three distinct virtual and anonymous surveys targeting three different groups of respondents: patients, caregivers, and health care professionals (Data S1–S3). The surveys were opened simultaneously and remained active for 3 months, from March 2024 to May 2024. The surveys for patients and caregivers comprised 7 questions. The first three questions focused on the patient's demographics, such as age, age of diagnosis, and current location. This was followed by an open question about their interpretation of the TS label and a closed question to rate their sentiment toward it on a satisfaction scale from 0 to 5, with 0 being not satisfied at all and 5 being completely satisfied. Additionally, respondents were presented with a list of 10 alternative terms for TS and asked to indicate their preference (single answer). An open-ended section allowed participants to share any additional comments. Caregivers expressed their views in the second part of the survey. Quantitative data were subjected to statistical analysis and qualitative data to thematic analysis. The health care professional survey comprised 6 questions, including geographical location and clinical role. The second part of the survey was identical to the caregivers and patient questionnaires. We disseminated these surveys through TS networks, including the ESSTS and MDS TS Study Groups. They were supplied with QR codes, which the participants could quickly scan. This initial pilot study received 421 responses from 26 countries, including 174 patients, 160 caregivers, and 89 health care professionals, of whom 38% have an expertise in neuropsychiatry. Of these, 242 responses were from the UK, and between 40 and 60 responses each from Germany, the USA, and Australia, with the remaining responses (50% of patients and carers will be used as a base to advocate for a new label. In future work, the concerns of patients regarding the continuity of support and services will be carefully considered. We will evaluate whether these concerns influence their perspectives on diagnostic labelling. We will canvas views from several countries, with planned involvement from partner organizations, including the TTAG (Tics and Tourette Across the Globe), MDS, and ESSTS communities. (1) Research project: A. Conception, B. Organization, C. Execution; (2) Statistical analysis: A. Design, B. Execution, C. Review and critique; (3) Manuscript: A. Writing of the first draft, B. Review and critique. G.R.: 1A, 1B, 1C, 2A, 2B, 2C, 3A, 3B O.M.: 1C, 2C, 3B S.A.: 1C, 2C, 3B L.C.: 1C, 2C, 3B A.H.: 1C, 2C, 3B D.M.: 1C, 2C, 3B N.M.D.: 1C, 2C, 3B K.R.M: 1C, 2C, 3B C.N.: 1C, 2C, 3B T.P.: 1C, 2C, 3B S.S.: 1C, 2C, 3B N.S.: 1C, 2C, 3B O.T.: 1C, 2C, 3B K.K.T.: 1C, 2C, 3B T.H.: 1A, 1B, 1C, 2A, 2B, 2C, 3A, 3B Ethical Compliance Statement: The authors confirm that the approval of an institutional review board was not required for this work. Informed consent was obtained from all the participants of this study. We confirm that we have read the journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. Funding Sources and Conflicts of Interest: No specific funding was received for this work. Financial Disclosures for the Previous 12 Months: Kirsten Müller-Vahl has received financial or material research support from DFG: GZ MU 1527/3-1 and GZ MU 1527/3-2 and Almirall Hermal GmbH. She has received consultants' and other honoraria from AlphaSights Ltd., Canopy, Canymed, DHMS Direct Health Medical Services Ltd./ Wellster Healthtech Group, Emalex, Eurox Group, Neuraxpharm, Sanity Group, Stadapharm GmbH, Swiss alpinapharm, Synendos Therapeutics AG, Tetrapharm, and Triaspharm. She is an advisory/scientific board member for Branchenverband Cannabiswirtschaft e.V. (BvCW), Sanity Group, Synendos Therapeutics AG, Syqe Medical Ltd., and Therapix Biosciences Ltd. She has received speaker's fees from Almirall, Bundesverband der pharmazeutischen Cannabinoidunternehmen (BPC), Cogitando GmbH, Emalex, Grow, Laleto GmbH, Landesamt für Soziales, Jugend und Versorgung Mainz, Medizinischer Dienst Westfalen Lippe, Noema, streamedup! GmbH, VBG—Unfallversicherung Hamburg, Vidal, and WeCann. She has received royalties from Elsevier, Medizinisch Wissenschaftliche Verlagsgesellschaft Berlin, and Kohlhammer. She is an associate editor for “Cannabis and Cannabinoid Research.” She is an editorial board member of “Medical Cannabis and Cannabinoids” and “MDPI-Reports” and a scientific board member for “Zeitschrift für Allgemeinmedizin.” The data that support the findings of this study are available from the corresponding author upon reasonable request. Data S1. Supplementary material for review and publication 1: caregiver survey on Tourette's syndrome (TS) label preference. This survey was administered to caregivers and/or parents of individuals with TS. It includes questions regarding their preferred diagnostic label for the condition. Data S2. Supplementary material for review and publication 2: health care professional survey on Tourette syndrome label preference. This survey was completed by health care professionals, some of whom diagnose and/or treat individuals with TS. It explores their preferred terminology when referring to the condition and their perspectives on different labels. Data S3. Supplementary material for review and publication 3: patient survey on Tourette's syndrome (TS) label preference. This survey was distributed to individuals diagnosed with TS. It enquires on their preferred diagnostic label and how different terms impact their perception of the condition. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Related Papers

• Susquehanna Chorale Spring Concert "Roots and Wings"(2017)
• → DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION(2018)
• → Genentech taps Affimed’s antibodies(2018)
• → KOMPLIKASI REGIONAL ANESTESI PADA PEDIATRIK(2023)
• → ИСПОЛЬЗОВAНИЕ ПОТЕНЦИAЛA СОЦИAЛЬНЫХ ПAРТНЕРОВ В ПОДГОТОВКЕ БУДУЩИХ ПЕДAГОГОВ(2024)